Abstract
We present the case of a 10-year old male child with severe incapacitating psoriasis resistant to multiple treatments. He was treated with etanercept successfully in our Dermatology Department. The use of etanercept in children and adolescents with severe psoriasis has been recently approved by the European Medicines Agency. Thus, it has become the first and only biological drug authorized for its use in the child population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
